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Edited by Robert BaroukiAbstract Pancreatic b-cell function continuously deteriorates
in type 2 diabetes despite optimal treatment regimens, which
has been attributed to hyperglycemia itself via formation of ex-
cess levels of reactive oxygen species (ROS). Glutathione perox-
idase GPx), by virtue of its ability to catabolize both H2O2 and
lipid peroxides, is uniquely positioned to protect tissues from
ROS. The level of this antioxidant in b cells is extremely low
and overexpression of GPx in islets provides enhanced protection
against oxidative stress. This suggests that GPx mimetics may
represent a valuable ancillary treatment that could add a novel
layer of protection for the b-cell.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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This review addresses the general area of cellular stress
through a consideration of the pancreatic islet b-cell and its
interactions with reactive oxygen species (ROS) under physio-
logic conditions, as well as under the pathophysiologic state of
diabetes mellitus and attendant hyperglycemia. It focuses on
the antioxidant enzyme glutathione peroxidase (GPx), an en-
zyme that is uniquely positioned in the ROS degradation path-
way to protect cells from excessive levels of hydrogen peroxide
(H2O2) and intracellular lipid peroxides. In contrast, catalase,
which also metabolizes H2O2, does not metabolize lipid perox-
ides. Pharmacologic insights and therapeutic suggestions are
provided from a consideration of molecular mechanisms in-
volved in ROS-induced defective insulin gene expression and
b-cell dysfunction.2. The pancreatic islet: physiology and pathophysiology
The islets of Langerhans are scattered throughout the exo-
crine pancreas and comprise only 2–3% of the pancreatic mass.
Islets contain four major cell types: a, b, d, and PP cells. These
cells secrete glucagon, insulin, somatostatin, and pancreatic*Corresponding author.
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secretion is glucose, but it can also be stimulated by amino
acids, other hormones, and certain drugs. Insulin secretion
ceases when the blood glucose reaches abnormally low levels,
thereby preventing worsening of hypoglycemia. The primary
regulators for glucagon secretion are just the opposite, i.e.
hypoglycemia stimulates glucagon secretion whereas hypergly-
cemia inhibits the secretion of this hormone. Somatostatin
secretion is stimulated by glucose and amino acids. Pancreatic
polypeptide is stimulated by hypoglycemia and another hor-
mone, secretin. The interplay of regulators of hormone secre-
tion from the pancreatic islet provides a sophisticated means
by which the products of islet cells regulate overall body
metabolism. Insulin is the primary regulator of blood glucose
and is essential for normal growth and storage of fuels in body
tissues. Absence of normal insulin secretion causes very high
levels of glucose and leads to diabetes. If excessive insulin is in-
jected from an exogenous source, blood glucose can be lowered
to abnormally low levels, termed hypoglycemia. In this situa-
tion, glucagon is normally secreted from alpha cells and recov-
ery from hypoglycemia begins. As soon as the blood glucose
returns to normal, glucagon secretion is inhibited. Somato-
statin is a local regulator of both insulin and glucagon
secretion by virtue of its capacity to inhibit secretion from
the b- and a-cell. The function of pancreatic polypeptide in hu-
mans is unknown.
Both insulin and glucagon have important metabolic targets.
The major function of these two partners is to ﬁnely regulate
blood glucose levels so that neither prolonged hypoglycemia
or hyperglycemia are allowed to develop. Insulin inhibits and
glucagon stimulates glycogenolysis in the liver, a process by
which stored glycogen is broken down into glucose for release
into the bloodstream. Insulin inhibits and glucagon stimulates
gluconeogenesis, a biochemical process by which amino acids
are used to synthesize glucose. Insulin inhibits and glucagon
stimulates lipolysis, a process by which stored triglyceride
within fat cells is released into the blood stream in the form
of fatty acids and glycerol. Insulin inhibits and glucagon stim-
ulates ketogenesis, a biochemical process in which free fatty
acids form ketones in the liver for release into the bloodstream.3. Physiology of ROS formation and regulation
The term ROS designates a large group of reactive oxygen
species that in physiological concentrations help maintainblished by Elsevier B.V. All rights reserved.
Fig. 1. Glutathione (GSH) metabolism. Cysteine, the rate limiting
aminoacid for GSH synthesis, along with glutamate and glycine, are
used by glutathione synthetase and the catalytic subunit of glutathione
cysteine ligase (GCLC) to synthesize GSH. Buthionine sulfoximine
(BSO) inhibits GCLC activity. GSH is used by glutathione peroxidase
(GPx) in a reduction reaction to metabolize hydrogen peroxide (H2O2)
and lipid peroxides into elemental oxygen and water. Catalase can also
metabolize H2O2, but not lipid peroxides. Superoxide dismutases 1 and
2 catabolize superoxide ions to form H2O2.
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and as participants in white blood cell defense against infec-
tion. It is also reasonable to postulate that physiologic
amounts of ROS regulate islet gene expression and facilitate
regulation of b-cell function. However, when ROS accumulate
in excess for prolonged periods of time, they cause chronic oxi-
dative stress and potentially adverse eﬀects. Antioxidant en-
zymes contained within host tissues are the ﬁrst line of
defense against excessive levels of ROS (Fig. 1). An important
consideration is the level of antioxidant host defenses within
the islet. Generally speaking, the highest levels of antioxidant
enzyme expression are in the liver, a major detoxiﬁcation cen-
ter. In contrast, it has been reported that the islet is among the
least well-endowed tissues in terms of intrinsic antioxidant en-
zyme expression and activity [1,2], including superoxide dismu-
tases (SOD-1, SOD-2), catalase, and glutathione peroxidase
(GPx). In contrast, gene expression of the catalytic subunit
of c-glutamylcysteine ligase (GCLC), the rate-limiting enzyme
for glutathione (GSH) synthesis, is well expressed in islets [3].
GSH is the major intrinsic antioxidant in cells, as well as being
a cofactor for GPx activity. Levels of GCLC mRNA are com-
parable to those found in liver and greater than those found in
muscle, lung and fat [3]. It has been reported, however, that
long-term exposure to high glucose concentrations decreases
GCLC expression in mesangial as well as retinal cells, and that
this is associated with a decrease in GSH levels [4,5].4. Hyperglycemia and oxidative stress
4.1. Clinical evidence in humans: markers of oxidative stress
Many clinical studies have documented that patients with
type 2 diabetes are subjected to chronic oxidative stress [6–
11]. Measurements using sophisticated laboratory techniques,
including high performance liquid chromatography, gas chro-
matography/mass spectrometry, and immunostaining of pan-
creas have been used. Markers for oxidative tissue damage,
such as 8-hydroxy-deoxyguanine; 4-hydroxy-2-nonenal;
8-epi-PGF2a; hydroperoxides; and oxidized DNA bases have
been reported to be elevated in serum, plasma, white blood
cells, and pancreas biopsies of patients with type 2 diabetes.Glutathione, the primary intracellular antioxidant, has been
studied extensively. Murakami et al. reported that red blood
cells from diabetic patients contain low levels of the reduced
form of glutathione (GSH), high levels of the oxidized form
(GSSG), and a 51% reduction in the GSH/GSSG ratio [12].
Sharma et al. also reported that type 2 diabetic patients in poor
glycemic control had depressed red blood cell GSH levels [13].
After decreasing red blood cell HbA1c levels by sulfonylurea
treatment, the red blood cell GSH levels increased twofold, al-
most reaching the values found in a non-diabetic control
group. Similar data were reported by Yoshida et al. who, in
addition, reported that activity of the rate-limiting enzyme of
GSH synthesis, c-glutamylcysteine synthase, increased with
improved glycemic control [14]. This group also reported that
red blood cell thiol transport was signiﬁcantly and inversely
correlated with levels of HbA1c.4.2. In vivo evidence in animals: eﬀects of antioxidants
The Zucker diabetic fatty (ZDF) rat is homozygous for deﬁ-
ciency of the leptin receptor, spontaneously develops obesity
and hyperglycemia, and has decreased insulin gene expression
after 6–7 weeks of age [15–19]. Seufert et al. [20] have found
that the development of hyperglycemia in this animal model
is associated with the loss of an important insulin promoter
activator, PDX-1. We designed experiments to examine
expression of PDX-1 (STF-1) and insulin in the ZDF animal
and ascertained whether prevention of hyperglycemia would
alter the deleterious changes in insulin gene expression and
PDX-1 binding to the insulin promoter. We designed studies
in which ZDF animals were either treated or not treated with
troglitazone given orally [21]. The drug was begun at 6 weeks
of age. By 16 weeks of age the untreated ZDF animals had
hyperglycemia and marked decreases in islet PDX-1 mRNA
levels, PDX-1 binding to DNA, insulin mRNA levels, and glu-
cose-induced insulin secretion. In contrast, the ZDF animals
treated with troglitazone did not develop as severe hyperglyce-
mia and had preserved levels of PDX-1 mRNA and nuclear
protein binding, insulin mRNA, and glucose-stimulated insu-
lin secretion [21]. These ﬁndings are consistent with the
hypothesis that progressive hyperglycemia in this animal mod-
el causes secondary eﬀects on insulin gene expression that are
associated with a decrease in PDX-1 gene expression. How-
ever, since troglitazone also has been reported to decrease cir-
culating triglycerides and free fatty acids, it is also possible that
its beneﬁcial eﬀects on insulin gene expression could be par-
tially explained by the avoidance of another pathophysiologic
state, lipotoxicity [22–24].
To diﬀerentiate glucotoxicity from lipotoxicity in the ZDF
animal, we treated animals with either bezaﬁbrate, a lipid-low-
ering drug that does not aﬀect plasma glucose levels, or phlo-
rizin, a drug that reduces plasma glucose without lowering
lipid levels. Despite lowering plasma triglyceride, bezaﬁbrate
was not eﬀective in preventing increased islet triglyceride con-
tent and did not prevent the associated decrease in insulin
mRNA levels [25]. On the other hand, phlorizin treatment pre-
vented hyperglycemia, lowered islet triglyceride content, and
preserved insulin mRNA levels without preventing hypertri-
glyceridemia. We concluded that glucose toxicity rather than
lipotoxicity was the more dominant force in the development
of progressive loss of insulin mRNA and insulin secretion in
ZDF animals.
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are interrelated. In vitro, prolonged exposure of isolated islets
to elevated levels of fatty acids impairs insulin gene expression
only in the presence of high glucose concentration [26]. Glu-
cose is rate-limiting for the incorporation of fatty-acids into
triglycerides [27] and forcing triglyceride synthesis in islets im-
pairs glucose-induced insulin secretion [28]. High-fat feeding
impairs insulin secretion in islets from hyperglycemic Goto-
Kakizaki (GK) rats, but not in islets from normoglycemic Wis-
tar rats or GK rats treated with insulin [29]. Thus, we proposed
that chronic hyperlipidemia might be deleterious only in the
context of concomitant hyperglycemia, whereas chronic hyper-
glycemia can cause islet dysfunction in the absence of hyperlip-
idemia [30].
In other experiments, the ZDF rat model was used to eval-
uate the hypothesis that the glucose toxicity observed in our
experiments was at least partially caused by chronic oxidative
stress. Hyperglycemia is known to be associated with oxidative
stress in clinical diabetes [6–14] and auto-oxidation of glucose
is known to generate reactive oxygen species [31]. Thus, we
treated ZDF animals with either N-acetylcysteine (NAC), a
powerful antioxidant [32], or placebo injection. Treatment
was begun at 6 weeks of age and carried through 12 weeks
of age. Measures of chronic oxidative stress were higher in
the ZDF rats that developed hyperglycemia compared to
ZDF rats treated with NAC. Associated with the increase of
oxidative stress markers was the development of accelerated
hyperglycemia, decreased glucose tolerance, decreased insulin
secretion, decreased PDX-1 binding to the insulin promoter,
and decreased insulin gene expression. In contrast, the ZDF
animals treated with NAC developed much less hyperglycemia
(Fig. 2) and had preserved PDX-1 DNA binding, insulin gene
expression, and nearly normal insulin secretion and glucose
tolerance. Similar ﬁndings were observed in parallel studies
using aminoguanidine, a drug that is both an antioxidant
and an inhibitor of glycosylation [33]. Control studies using
an inhibitor of nitric oxide synthase did not demonstrate pre-
vention of hyperglycemia and preservation of insulin gene
expression. These ﬁndings point to chronic oxidative stress
as a potential mechanism of action for glucose toxicity. In this
context, it is interesting to note that troglitazone, a drug shown
to prevent diabetes in the ZDF animal, is also an antioxidant.Fig. 2. Plasma glucose levels in Zucker Diabetic Fatty (ZDF) rats, a
genetic model of type 2 diabetes, who were treated with placebo,
n-acetylcysteine, or aminoguanidine beginning at 6 weeks of age. Both
drugs are antioxidants and both drugs ameliorated the degree of
hyperglycemia developed by the animals. Zucker lean controls (ZLC)
that do not develop hyperglycemia are shown for comparison. Taken
from Ref. [32].5. Molecular mechanisms of action of glucose toxicity leading to
oxidative stress
Much of the early work addressing molecular mechanisms of
glucose toxicity in b cells was performed with the HIT-T15 cell
line. We observed that HIT-T15 cells chronically cultured for 6
months in media containing 11.1 mM glucose, a concentration
exceeding that necessary to elicit maximal insulin responses,
caused loss of insulin mRNA, greatly diminished levels of insu-
lin content, and almost complete disappearance of insulin
secretion [33]. In contrast, HIT-T15 cells cultured serially in
media containing 0.8 mM glucose (minimally stimulatory for
insulin secretion) for 6 months retained insulin mRNA, insulin
content, and insulin responsivity to glucose. This suggested
that glucose toxicity might be explained by molecular mecha-
nisms involving insulin gene expression and subsequent insulin
synthesis. In further studies, HIT-T15 cells were transiently
transfected with a chloramphenicol acetyl transferase (CAT)
reporter gene controlled by the 5 0-regulatory region of the hu-
man insulin gene (INSCAT). Early passages of HIT cells cul-
tured in supraphysiologic glucose concentrations readily
expressed INSCAT, whereas late passages of cells expressed
only 29% of the CAT activity expressed in earlier passages
[34]. In contrast, late passages of cells cultured in 0.8 mM glu-
cose retained the ability to express reporter gene activity to a
level of 70–100% of the activity observed in earlier passages.
As part of our studies, we mutated the motif in the insulin pro-
moter to which PDX-1 binds and observed marked decreases
in INSCAT activity in early and late passages of HIT-T15
cells, thereby demonstrating its importance as a regulator of
transcription. Northern analysis indicated a marked reduction
in the steady-state levels of PDX-1 mRNA in HIT-T15 cells
chronically cultured in supraphysiologic glucose concentration
(Fig. 3), which could not be accounted for by changes in the
rate of PDX-1 gene transcription assessed by nuclear run-on
analysis. We concluded that the molecular mechanism by
which chronic exposure of pancreatic islet b cells to high glu-
cose concentrations can paradoxically decrease insulin gene.
transcription (glucose toxicity) involves alteration of the ability
of PDX-1 to bind to the insulin gene promoter.
We also found that decreased levels of RIPE-3b1-activator,
recently identiﬁed as MafA [35–38], also plays a role in glucose
toxicity of the b-cell. We demonstrated that the binding and
trans-activation functions of MafA were reduced in HIT-T15
cells chronically cultured in media containing 11.1 mM glucose
[39]. In contrast, there was no diﬀerence in another important
transcription factor, the insulin control element (ICE) activa-
tor. Using a luciferase reporter vector, we demonstrated that
mutation of MafA binding site caused marked diminution of
reporter gene activity in HIT-T15 cells. We concluded that
glucotoxic consequences on insulin gene expression involve
deﬁciencies of both MafA and PDX-1 proteins.
Subsequent work by Harmon et al. [39] assessed the tempo-
ral sequence of the loss of the PDX-1 and MafA in HIT-T15
cells chronically cultured in supraphysiologic glucose concen-
trations. MafA binding activity to DNA was decreased below
25% of control by passage 81, whereas PDX-1 binding re-
mained at normal levels through passage 100 and did not de-
crease to 25% of control levels until passage 106. This cell
line begins to lose insulin gene expression by passage 80–85,
suggesting that loss of MafA may play an early and dominant
role in glucotoxic events. Other studies examined whether
Fig. 3. Molecular mechanisms of actions leading to defective insulin gene expression in glucotoxic b cells. In this model, insulin gene transcription is
intrinsically normal, but gene expression of two critical transcription factors, PDX-1 and MafA, is not. Normally, PDX-1 binds to the insulin
promoter at three sites, A1, A3, and A5. MafA binds to C1 only. During the development of glucose toxicity, PDX-1 fails to become expressed
because of a post-transcriptional defect, and MafA fails to become expressed because of a post-translational defect. Consequently, insulin gene
expression at the mRNA level decreases, as does insulin stores and glucose-induced insulin secretion. Taken from Ref. [43].
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cDNA would restore insulin promoter activity. We observed
that reconstitution with PDX-1 cDNA of HIT-T15 cells chron-
ically cultured in media containing 11.1 mM glucose partially
regained insulin promoter activity [39]. In later work, North-
ern analysis of glucotoxic HIT-T15 cells revealed normal
amounts of MafA mRNA, but Western analysis demonstrated
a 97 ± 1% reduction in MafA protein [40]. Since antioxidants
had already been shown to prevent the adverse eﬀects of glu-
cose toxicity on b-cell function both in vivo and in vitro, we
chronically cultured HIT-T15 cells with the antioxidant N-ace-
tylcysteine (NAC) and observed prevention of MafA protein
loss in late passages cultured in media containing high glucoseFig. 4. Preventive eﬀects of adenoviral infection of GPx cDNA in isolated is
decreases insulin gene expression and glucose-induced insulin secretion from
GPx cDNA increase intrinsic GPx activity in islets sixfold (top panel) and pr
with virus not containing GPx (Ad) has no eﬀects on islets under control c
panels). Taken from Ref. [42].concentrations. Additionally, transient transfection of PDX-1
and MafA cDNA into glucotoxic cells increased PDX-1 and
MafA protein levels. They individually increased insulin pro-
moter activity, and in combination transfection completely re-
stored insulin promoter activity. This recovery of promoter
activity following transient transfection had no eﬀect on
endogenous insulin mRNA. However, adenoviral infection of
MafA and PDX-1 signiﬁcantly increased endogenous insulin
mRNA levels by 93% [40].
Studies assessing molecular mechanisms for glucose toxicity
using isolated islets were performed by Briaud et al. [41] who
cultured isolated rat islets for up to 6 weeks in either normal
(5.6 mM) or supraphysiologic (16.7 mM) glucose concentra-lets against the oxidative eﬀects of ribose. Ribose in non-infected cells
rat islets in vitro (two lower panels). Adenoviral infection of islets with
events the adverse eﬀects of ribose on islets (bottom panels). Infection
onditions or on the adverse eﬀects of ribose on islet function (bottom
R.P. Robertson, J.S. Harmon / FEBS Letters 581 (2007) 3743–3748 3747tions. Insulin mRNA levels were approximately twofold lower
in islets cultured in high glucose than in islets cultured in nor-
mal glucose after 6 weeks of culture.6. GPx in pancreatic islets
6.1. In vitro levels: rat and human islets
As indicated above, GPx expression at the mRNA and pro-
tein levels has been reported to be very low in rodent islets and
absent in a b-cell line [1,2]. No published GPx data from hu-
man islets are available, but recently we have recently detected
only minimal amounts of GPx protein and activity in islets iso-
lated from 8 human donors (unpublished data). In contrast,
SOD-1 and SOD-2, are detectable in rodent and human islets
[1,2, and our unpublished human islet data], although these
levels are lower than levels found in the liver. Catalase expres-
sion has been reported to be virtually undetectable in rodent
islets [1,2] and our unpublished work detects only minimal
amounts of catalase protein and activity in human islets. These
assessments in rodent and human islets lead to the conclusion
that a rational strategy for enhancing protection of b cells
against oxidative stress would involve b-cell-speciﬁc overex-
pression of GPx. Overexpression of catalase might also be
helpful. However, because it catabolizes only H2O2 and not
intracellular lipid peroxides, GPx overexpression would seem
to be the better strategy.6.2. Beneﬁcial eﬀects of GPx overexpression on insulin gene
expression, insulin secretion, and insulin content
To evaluate the hypothesis that GPx overexpression might
protect the b cell from oxidative stress, we ﬁrst determined
whether high glucose concentrations increase intraislet ROS
levels [42]. Using ﬂow cytometry and a ﬂuorescent dye detec-
tion system, we observed that high glucose concentrations in-
creased intracellular peroxide levels in human islets and HIT-
T15 cells. Inhibition of c-glutamylcysteine ligase by buthionine
sulfoximine augmented the increase in islet peroxide and ri-
bose-induced decreases in insulin mRNA levels, content, and
secretion in islets and HIT-T15 cells. Adenoviral overexpres-
sion of GPx increased GPx activity and protected islets against
these adverse eﬀects of ribose ([43]; Fig. 4).7. Conclusions
The normal pancreatic islet has intrinsincally low levels of
antioxidant enzyme gene expression, protein expression and
activities. No explanation is available for this ﬁnding, but a
possibility is that low levels of ROS facilitate regulation of
insulin gene expression and b-cell function. In contrast, exces-
sive concentrations of ROS decrease insulin gene expression
and insulin secretion and even damage the islet. High glucose
concentrations have been shown to increase intraislet ROS
concentrations and clinical measures of oxidative stress are ele-
vated in people with type 2 diabetes mellitus. This raises the
question whether prolonged hyperglycemia might create a sit-
uation of double jeopardy for the b-cell. In this scenario, the
initial genetic cause of type 2 diabetes causes b-cell failure lead-
ing to chronic hyperglycemia, which in turn worsens the degree
of b-cell failure via further b-cell damage by ROS formed byhigh glucose concentrations. This hypothesis has been sup-
ported by in vitro and in vivo demonstrations that antioxi-
dants protect b-cell lines and rodent models of type 2
diabetes against oxidative stress, thereby preserving insulin
gene expression and b-cell function. That GPx overexpression
in islets protects b cells from oxidative stress sets the stage for
an assessment of whether transgenic GPx overexpression in b
cells might protect animal models of type 2 diabetes and there-
by ameliorate their natural development of hyperglycemia. If
so, this will point the way towards the development of GPx
mimetics that might be used clinically to provide ancillary pro-
tection against the adverse eﬀects of chronic oxidative stress
from chronic hyperglycemia in the diabetic patient, who only
rarely achieves perfectly controlled glucose levels by conven-
tional anti-diabetic therapy.
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